A study reporting AdooQ A10735 found that pirarubicin entered SVR angiosarcoma cells more slowly than idarubicin or aclarubicin. Short pirarubicin exposures reduced MTS-based viability in a concentration- and exposure-dependent manner after a 24 h drug-free recovery period. These results describe the tested cell model and exposure schedule, rather than a universal potency value. [2]
Pirarubicin uptake in SVR angiosarcoma cells
Cell-based study · Murine SVR angiosarcoma cells [2]
Intracellular pirarubicin accumulated over the first hour. Uptake was slower than idarubicin and aclarubicin in the same experimental comparison; fitted lines are model predictions, while plotted points are experimental measurements.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 5 and 10 μg/mL
- Exposure duration
- Sampling during the first 60 min, as plotted in Figure 2
- Method
- Exposure in complete culture medium at 37°C
- Reported limits
- The Drugs section allows water or DMSO reconstitution without assigning the solvent to each compound; independent uptake replicate count is not specified in the selected text.
Methods and source locations
Compound reported in the paper: Pirarubicin; Compound label in the paper: PIR
The authors identify AdooQ A10735 as their pirarubicin source. This is historical reported use, not validation of a current lot.
Materials and methods: Cell culture, Drugs, Cellular drug uptake measurements; Results: Cellular drug uptake model; Figure 2a–d
Cell-associated drug extracted and normalized per 10^6 cells: Drug extraction followed by fluorescence at Ex 485/Em 590 nm, calibrated against free drug in the same extraction solution; normalized to counted cells. No curve-derived numerical concentrations adopted. — Figure 2a–d and caption; Cellular drug uptake measurements; Results: Cellular drug uptake model
Short-exposure pirarubicin cytotoxicity in SVR cells
Cell-based study · Murine SVR angiosarcoma cells [2]
Pirarubicin reduced MTS-based viability with increasing concentration and longer exposure. The 15, 60 and 180 min exposure groups belong to one dose–time experiment. Viability was normalized to the 0 μg/mL drug control after a drug-free recovery period.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 0.001, 0.01, 0.1, 1, 10 and 100 μg/mL
- Exposure duration
- 15, 60 or 180 min exposure, followed by washing and 24 h in drug-free complete medium before the MTS assay
- Method
- Short exposure followed by recovery; MTS metabolic viability assay
- Reported limits
- The solvent for pirarubicin is not individually assigned. The 4–6 replicates are wells, not stated independent biological experiments. Table 4 does not specify its IC50 exposure duration or define its ± term, so those numerical potencies are not adopted.
Methods and source locations
Compound reported in the paper: Pirarubicin; Compound label in the paper: PIR
The authors identify AdooQ A10735 as their pirarubicin source. This is historical reported use, not validation of a current lot.
Cell viability assays; Cell cytotoxicity model; Results: Cytotoxicity model; Figure 3c and caption
MTS signal relative to the 0 μg/mL control: MTS absorbance at 490 nm after drug removal/washing and 24 h in fresh medium; no-cell background subtracted; 4–6 wells per condition. Plotted experimental points distinguished from fitted curves. — Cell viability assays; Figure 3c; Cell cytotoxicity model
DNA-damage marker and Akt/ERK responses to pirarubicin
Cell-based study · Human UMUC3 and murine MB49 bladder cancer cells [1]
Pirarubicin treatment increased phosphorylated H2A.X together with Akt and Erk1/2 phosphorylation relative to the zero-drug group. This supports a DNA-damage-associated cellular response accompanied by survival-pathway activation; it is not a direct topoisomerase-II binding or inhibition experiment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 50, 100 and 200 nM
- Exposure duration
- 36 h
- Method
- Western blot analysis of treated and zero-THP cells
- Vehicle
- Stock: DMSO; final solvent-matched control not explicitly described
- Reported limits
- Final DMSO concentration and whether it was equalized between dose groups are not stated. Direct target occupancy, topoisomerase-II inhibition potency and DNA cleavage were not measured in this adopted experiment.
Methods and source locations
Compound reported in the paper: Pirarubicin; Compound label in the paper: THP
Results concern the paper’s supplier material described as pirarubicin; they do not establish AdooQ lot equivalence or a formulation-independent response.
Reagents; Cell Lines and Culture Conditions; Western Blotting; Results first subsection; Figure 1A–B
Phosphorylated H2A.X, Akt and Erk1/2: Western blotting with β-actin loading control and total Akt/Erk comparators; ImageJ densitometry. Replicate independence is not defined in the caption; no exact fold changes inferred. — Figure 1A–B and caption; Western Blotting; Results: THP Activates Akt and ERK in Addition to Inducing DNA Damage in Bladder Cancer Cells